More on MRK
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $150.91 |
|
|||
| Open | $151.32 | ||||
| 52 Wk High | $65.46 | ||||
| 52 Wk Low | $47.97 | ||||
| Day High | $152.01 | ||||
| Day Low | $146.89 | ||||
| P/E | 100.73 | ||||
| EPS | $1.47 | ||||
| Volume | 9,703,668 | ||||
- Merck (MRK) Reiterated at Neutral by Cantor Fitzgerald
- FDA updates Merck's Winrevair label with early PAH trial data
- U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH
- Japan approves Merck's subcutaneous pembrolizumab for all Keytruda uses
- Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
- EU panel backs Merck's Keytruda plus Padcev for bladder cancer
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIB
- Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV
- Perspective Therapeutics and Merck to test cancer drug combination
- Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
Entities mentioned with MRK
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
